(Q46744850)

24 December 2017

title

Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients (English)

1 reference

24 December 2017

0 references

13

Pier Luigi Zinzani

1 reference

24 December 2017

Emilio Berti

Emilio Berti

6

0 references

Michele Baccarani

12

Michele Baccarani

1 reference

24 December 2017

1

Enrica Marchi

1 reference

24 December 2017

Stefano A Pileri

11

Stefano Pileri

1 reference

24 December 2017

Livio Pagano

7

Livio Pagano

1 reference

24 December 2017

author name string

Lapo Alinari

2

1 reference

24 December 2017

Monica Tani

3

1 reference

24 December 2017

Vittorio Stefoni

4

1 reference

24 December 2017

Nicola Pimpinelli

5

1 reference

24 December 2017

Maria Grazia Bernengo

8

1 reference

24 December 2017

Francesco Zaja

9

1 reference

24 December 2017

Serena Rupoli

10

1 reference

24 December 2017

language of work or name

English

0 references

publication date

1 December 2005

1 reference

24 December 2017

published in

Cancer

1 reference

24 December 2017

volume

104

1 reference

24 December 2017

issue

11

1 reference

24 December 2017

page(s)

2437-2441

1 reference

24 December 2017

World Health Organization classification of hematopoietic and lymphoid tissues: implications for dermatology

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21449

7 January 2021

Treatment of cutaneous T cell lymphoma: current status and future directions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21449

7 January 2021

Current management strategies for cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21449

7 January 2021

The potential therapeutic role of interleukin-12 in cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21449

7 January 2021

A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21449

7 January 2021

Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21449

7 January 2021

Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21449

7 January 2021

The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21449

7 January 2021

Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21449

7 January 2021

Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21449

7 January 2021

The role of 2-chlorodeoxyadenosine in the treatment of patients with refractory angioimmunoblastic lymphadenopathy with dysproteinemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21449

7 January 2021

Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21449

7 January 2021

Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21449

7 January 2021

Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21449

7 January 2021

TNM classification of malignant tumors. A comparison between the new (1987) and the old editions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21449

7 January 2021

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21449

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21449

7 January 2021

Treatment of prolymphocytic leukemia with cladribine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21449

7 January 2021

Pentostatin in T-cell malignancies--a phase II trial of the EORTC. Leukemia Cooperative Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21449

7 January 2021

Pentostatin therapy of T-cell lymphomas with cutaneous manifestations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21449

7 January 2021

Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21449

7 January 2021

Gemcitabine and cisplatin in refractory malignant lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21449

7 January 2021

Pilot study of fixed-infusion rate gemcitabine with Cisplatin and dexamethasone in patients with relapsed or refractory lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21449

7 January 2021

Identifiers

DOI

10.1002/CNCR.21449

1 reference

24 December 2017

1 reference

24 December 2017